本文選題：皮下注射免疫治療 + 舌下免疫治療　； 參考：《重慶醫(yī)科大學》2014年碩士論文

【摘要】：因個體過敏體質、外界環(huán)境以及多基因遺傳的影響，變應性哮喘發(fā)病率呈逐漸上升趨勢。特異性免疫治療（Specific immunotherapy，SIT）是除避免接觸變應原、藥物治療以外的一種新的治療方式；是唯一針對病因學的治療，可以通過免疫調節(jié)機制改變變應性疾病的自然病程，防止病情進一步惡化。在臨床實驗研究中，我們發(fā)現(xiàn)它不僅能夠減輕哮喘癥狀、減少藥物需求，還能預防過敏性鼻炎患兒向變應性哮喘的發(fā)展。另外，即使終止SIT治療，其預防和控制哮喘的療效亦可持久存在。皮下注射和舌下含服（或滴定）是目前變應性哮喘SIT研究和應用最多的兩條途徑。為了進一步提高SIT的療效及安全性、縮短療程，人們在不斷尋求新的解決方案（如：尋求SIT新的途徑、研發(fā)新型變應原制品）。自SIT提出至今，已證明了SIT應用于呼吸系統(tǒng)變應性疾病的優(yōu)勢，但仍然存在一些問題值得我們思考。為能進一步認識SIT、促進臨床研究以及推動該治療方式日后在臨床中的廣泛應用，這里就變應性哮喘的特異性免疫治療作一簡單的綜述。
[Abstract]:The incidence of allergic asthma increased gradually due to the influence of allergy constitution, external environment and polygene inheritance. Specific immunotherapy (SITs) is a new method of treatment in addition to avoiding exposure to allergens and drug therapy. It is the only treatment aimed at etiology and can alter the natural course of allergic diseases through immunomodulatory mechanisms. Prevent further deterioration of the disease. In clinical studies, we found that it can not only reduce the symptoms of asthma, reduce the demand for drugs, but also prevent allergic rhinitis children from developing into allergic asthma. In addition, the efficacy of the prevention and control of asthma can be sustained even if the sit therapy is terminated. Subcutaneous injection and sublingual administration (or titration) are the two most widely used approaches in the study and application of sit in allergic asthma. In order to further improve the efficacy and safety of sit, shorten the course of treatment, people are constantly looking for new solutions (for example, seek new approaches to sit, research and development of new allergen products. Since sit was put forward, it has proved the superiority of sit in the application of respiratory allergic diseases, but there are still some problems to be considered. In order to further understand site, promote clinical research and promote the wide application of this treatment in the future, this paper makes a brief review on specific immunotherapy of allergic asthma.
【學位授予單位】：重慶醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R562.25

【參考文獻】

相關期刊論文 前5條

1 張忠芳;何韶衡;;變態(tài)反應疾病免疫治療機制的研究進展[J];廣東醫(yī)學;2006年09期

2 鄭伯強;王桂蘭;楊賽;;粉塵螨滴劑舌下特異性免疫治療對兒童咳嗽變異性哮喘的有效性[J];中國當代兒科雜志;2012年08期

3 王爾靜,金燁;塵螨代謝產(chǎn)物制劑透皮療法防治小兒哮喘30例報告[J];臨床兒科雜志;1994年02期

4 肖曉雄;黃東明;崔碧云;賴旭新;Birgitte Gjesing;Michael Spangfort;鐘南山;;屋塵螨脫敏治療對變應性鼻炎及哮喘患者血清粉塵螨特異性IgG_4抗體的影響[J];中華臨床免疫和變態(tài)反應雜志;2009年01期

5 張曉巖;林江濤;;支氣管哮喘的流行病學及發(fā)病危險因素[J];中華結核和呼吸雜志;2007年07期

，

本文編號：2017571